LENZ Therapeutics, Inc.
NASDAQ: LENZSouth San Francisco, US · Founded 2019 · 2 known investors
Find your way into LENZ Therapeutics, Inc.
23 people in our graph share verified history with the LENZ Therapeutics, Inc. team — schools, employers, funds. One of them is your warm intro.
Jack Nielsenunlockedknows Katherine Stultz · together at Ocelot Bio (overlapped)
knows the team · via 4D Path
×4knows the team · via Biotech CEO Sisterhood
×3knows the team · via Kronos Bio
×3knows the team · via ConvaTec
Late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision.
Founders & leadership
JL
Josh LehrerExecutive
KS
Katherine StultzinExecutiveKatherine Stultz is an executive leader with experience in biotech company leadership, clinical development, and commercialization across multiple organizations and board roles.
PG
Philip GutryExecutive
ES
Evert SchimmelpenninkChief Executive Officer, President, Secretary, and Director
DC
Daniel ChevallardChief Financial Officer
SO
Shawn OlssonChief Commercial Officer
MO
Marc OdrichChief Medical Officer
Board
AB
Abraham BassanBoard director
JD
CR
PK
Perry KarsenBoard director
JJ
Joe JimenezBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$150.7M disclosed across 1 round · 2021
▶$150.7MraisedMar 2021 · 35 investors · BiotechnologyRule 506(b)
▶$150.7MraisedMar 2021 · 35 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Perry KarsenDirector
- Abraham BassanDirector
- Josh LehrerExecutive Officer, Director
- Katherine StultzExecutive Officer
- Philip GutryExecutive Officer
- Jerel DavisDirector
- Joe JimenezDirector
- Matthew PorteusDirector
- Carlo RizzutoDirector
- Maria Grazia RoncaroloDirector
- Offering amount
- $150.7M
- Amount sold
- $150.7M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$951.6Mvaluation at IPOJun 2021 · $17.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Frequently asked questions
- What does LENZ Therapeutics, Inc. do?
- Late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision.
- Who are LENZ Therapeutics, Inc.'s investors?
- LENZ Therapeutics, Inc.'s investors include Samsara BioCapital, Versant Ventures.
- How much funding has LENZ Therapeutics, Inc. raised?
- LENZ Therapeutics, Inc. has disclosed $150.7M raised across 1 round.
- Where is LENZ Therapeutics, Inc. headquartered?
- LENZ Therapeutics, Inc. is headquartered in South San Francisco, US.